Human subcutaneous adipose tissue LPIN1 expression in obesity, type 2 diabetes mellitus, and human immunodeficiency virus--associated lipodystrophy syndrome

Metabolism: Clinical and Experimental

Volumn 56, Issue 11, 2007, Pages 1518-1526

  Miranda, Merce ^a   Chacón, Matilde R ^a   Gómez, José ^b   Megía, Ana ^a   Ceperuelo Mallafré, Victòria ^a   Veloso, Sergi ^a   Saumoy, María ^a   Gallart, Lluís ^a   Richart, Cristóbal ^a   Fernández Real, Jose Manuel ^c   Vendrell, Joan ^a  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 6; MESSENGER RNA; NUCLEAR PROTEIN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN LPIN1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETES MELLITUS; FEMALE; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; MALE; MIDDLE AGED; NUCLEAR PROTEINS; OBESITY; SUBCUTANEOUS FAT;

EID: 35348903414     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.06.019     Document Type: Article

References (31)

1. Reitman M.L. The fat and thin of lipin. Cell Metab 1 (2005) 5-6
2. Phan J., Peterfy M., and Reue K. Lipin expression preceding peroxisome proliferator-activated receptor-gamma is critical for adipogenesis in vivo and in vitro. J Biol Chem 279 (2004) 29558-29564
3. Peterfy M., Phan J., Xu P., and Reue K. Lipodystrophy in the fld mouse results from mutation of a new gene encoding a nuclear protein, lipin. Nat Genet 27 (2001) 121-124
4. Reue K., Xu P., Wang X.P., and Slavin B.G. Adipose tissue deficiency, glucose intolerance, and increased atherosclerosis result from mutation in the mouse fatty liver dystrophy (fld) gene. J Lipid Res 41 (2000) 1067-1076
5. Phan J., and Reue K. Lipin, a lipodystrophy and obesity gene. Cell Metab 1 (2005) 73-83
6. Huffman T.A., Mothe-Satney I., and Lawrence Jr. J.C. Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin. Proc Natl Acad Sci U S A 99 (2002) 1047-1052
7. Han G.S., Wu W.I., and Carman G.M. The Saccharomyces cerevisiae lipin homolog is a Mg2+-dependent phosphatidate phosphatase enzyme. J Biol Chem 281 (2006) 9210-9218
8. Harris T.E., Huffman T.A., Chi A., Shabanowitz J., Hunt D.F., Kumar A., et al. Insulin controls subcellular localization and multisite phosphorylation of the phosphatidic acid phosphatase, lipin 1. J Biol Chem 282 (2007) 277-286
9. Donkor J., Sariahmetoglu M., Dewald J., Brindley D.N., and Reue K. Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns. J Biol Chem 282 (2007) 3450-3457
10. Ruvinsky I., and Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 31 (2006) 342-348
11. Fang Y., Park I.H., Wu A.L., Du G., Huang P., Frohman M.A., et al. PLD1 regulates mTOR signaling and mediates Cdc42 activation of S6K1. Curr Biol 13 (2003) 2037-2044
12. Suviolahti E., Reue K., Cantor R.M., Phan J., Gentile M., Naukkarinen J., et al. Cross-species analyses implicate lipin 1 involvement in human glucose metabolism. Hum Mol Genet 15 (2006) 377-386
13. Yao-Borengasser A., Rasouli N., Varma V., Miles L.M., Phanavanh B., Starks T.N., et al. Lipin expression is attenuated in adipose tissue of insulin-resistant human subjects and increases with peroxisome proliferator-activated receptor gamma activation. Diabetes 55 (2006) 2811-2818
14. van Harmelen V., Ryden M., Sjolin E., and Hoffstedt J. A role of lipin in human obesity and insulin resistance: relation with adipocyte glucose transport and GLUT4 expression. J Lipid Res 48 (2007) 201-206
15. Lindegaard B., Larsen L.F., Hansen A.B., Gerstoft J., Pedersen B.K., and Reue K. Adipose tissue lipin expression levels distinguish HIV patients with and without lipodystrophy. Int J Obes 31 (2007) 449-456
16. Fernandez-Real J.M., and Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24 (2003) 278-301
17. Lihn A.S., Richelsen B., Pedersen S.B., Haugaard S.B., Rathje G.B., Madsbad S., et al. Increased expression of TNFα, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 285 (2003) E1072-E1080
18. World Health Organization. Obesity: preventing and managing the global epidemic. WHO technical report series 894 (2000), World Health Organization, Geneva (Switzerland) 8-9
19. Domingo P., Vidal F., Domingo J.C., Veloso S., Sambeat M.A., Torres F., et al. Tumour necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneous adipocyte apoptosis. Eur J Clin Invest 35 (2005) 771-780
20. Christeff N., Melchior J.C., de Truchis P., Perronne C., Nunez E.A., and Gougeon M.L. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS 13 (1999) 2251-2260
21. Fernandez-Real J.M., Broch M., Ricart W., Casamitjana R., Gutierrez C., Vendrell J., et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes 47 (1998) 1757-1762
22. Peterfy M., Phan J., and Reue K. Alternatively spliced lipin isoforms exhibit distinct expression pattern, subcellular localization, and role in adipogenesis. J Biol Chem 280 (2005) 32883-32889
23. Finck B.N., Gropler M.C., Chen Z., Leone T.C., Croce M.A., Harris T.E., et al. Lpin 1 is an inducible amplifier of the hepatic PGC-1α/PPARα regulatory pathway. Cell Metabolism 4 (2006) 199-210
24. Testerink C., and Munnik T. Phosphatidic acid: a multifunctional stress signaling lipid in plants. Trends Plant Sci 10 (2005) 368-375
25. Behrens G., Dejam A., Schmidt H., Balks H.J., Brabant G., Korner T., et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13 (1999) F63-F70
26. Vigouroux C., Gharakhanian S., Salhi Y., Nguyen T.H., Chevenne D., Capeau J., et al. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab 25 (1999) 225-232
27. Cancello R., and Clement K. Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. BJOG 113 (2006) 1141-1147
28. Jones S.P., Qazi N., Morelese J., Lebrecht D., Sutinen J., Yki-Jarvinen H., et al. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. J Acquir Immune Defic Syndr 40 (2005) 565-572
29. Jenwitheesuk E., and Samudrala R. Virtual screening of HIV-1 protease inhibitors against human cytomegalovirus protease using docking and molecular dynamics. AIDS 19 (2005) 529-533
30. Jan V., Cervera P., Maachi M., Baudrimont M., Kim M., Vidal H., et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 9 (2004) 555-564
31. Kannisto K., Sutinen J., Korsheninnikova E., Fisher R.M., Ehrenborg E., Gertow K., et al. Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 17 (2003) 1753-1762